Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Berndt Modig
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 148
- Beta
- -2.32
- Country
- CH
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 38.21
Financials
Net Income
$-47.84MEBITDA
$-50.66MFree Cash Flow
$-37.83MEPS (diluted)
$-0.70Shares Outstanding (diluted)
68.07M+113.8%Operating Expenses
$50.79MCash & Debt
$318.28MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-175.70M | $-2.97 |
| 2024 | $0.00 | $-134.22M | $-2.48 |
| 2023 | $0.00 | $-100.88M | $-2.63 |
| 2022 | $0.00 | $-76.33M | $-2.27 |
| 2021 | $0.00 | $-42.73M | $-1.41 |
| 2020 | $0.00 | $-29.62M | $-0.85 |
| 2019 | $0.00 | $-8.98M | $-0.25 |
| 2018 | $0.00 | $-4.31M | $-0.14 |
Valuation
PHVShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·20d ago·Positive
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win Pharvaris N.V. maintains a 'Strong Buy' rating following pivotal phase 3 wins for both on-demand and prophylactic HAE therapies. PHVS achieved rapid symptom relief in RAPIDe-3 [median 1.28 hours, p
View source ↗ - Newsseekingalpha.com·27d ago·Neutral
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript
View source ↗ - Newsglobenewswire.com·33d ago·Negative
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026 ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the oral and poster presentations from th…
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the secon
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.82 per share
Typical surprise -8.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.81 vs $-0.75miss
- Tue, May 12$-0.70 vs $-0.82beat
- Thu, Apr 2$-0.85 vs $-0.71miss
- Wed, Nov 12$-0.70 vs $-0.78beat
- Tue, Aug 12$-0.94 vs $-0.87miss
- Tue, May 13$-0.89 vs $-0.80miss
Estimates and results for PHVS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PHVS officers and directors.
- Bought
- —
- Sold
- $26.5m
0 trades
40 trades
- Monges Vivianesold
- Schikan Johannes Gerardus Christiaan Petrussold
- Nassif David W.sold
- Lu Pengsold
- Schikan Johannes Gerardus Christiaan Petrussold
- Bjork Elisabethsold
- Glassman Robertsold
- Lesage Annesold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PHVS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.